Ten nonsmoking patients, suffering from mild bronchial asthma participated in the study (mean age 30±9 years, 5 men, 5 women). Asthma was diagnosed based on GINA 2008 criteria. The patients were free of any medication, at least 7 days before, and had not suffered from any infectious diseases including upper respiratory tract infections for at least 3 months prior to the study. Patients who did not meet these criteria were excluded from the study.

Bronchial Asthma

6 ml of apocynin of total dose 3 mg (0.5 mg/ml dissolved in sterile 0.9% NaCl as the study drug) has been nebulized for 15-20 min through the mouthpiece with using of a nose clip. A nebulizer Pulmo Aide AP-50 (DeVilbiss; Richmond, VA) was used (mass median aerosol diameter 3.1 mm, output 0.3 ml/min.)

Apocynin nebulization

Medical University of Lodz

Inhaled Apocynin Decreases Reactive Oxygen Species Concentrations in Exhaled Breath Condensate in Mild Asthmatics

Rafal Pawliczak

Medical Universtity of Lodz

Ministry of Science and Higher Education, Poland

Obstructive Lung Disease

Chronic Obstructive Pulmonary Disease

Asthma

Each dose of AKL1 or placebo will consist of two capsules which will be swallowed twice daily for 8 weeks.
The morning dose of study medication should be taken at approximately the same time each morning between 7:00 am and 10:00 am and should consist of two 500 mg capsules and then repeated between 7.00 pm and 10 pm.

AKL1

University of East Anglia

Treatment With AKL1 in Obstructive Airways Disease (The TAKL Study)

An Investigation of the Safety and Efficacy of Oral AKL1 in Patients Diagnosed With Obstructive Lung Disease

Dr Andrew M Wilson

apocynin

kašalj

cough

apocynin/kašalj

Inhaled Apocynin Decreases Reactive Oxygen Species Concentrations in Exhaled Breath Condensate in Mild Asthmatics

Treatment With AKL1 in Obstructive Airways Disease (The TAKL Study)

Najkompletnija baza ljekovitog bilja potpomognuta znanošću